ResultsIQ › Latest results › Indo Borax & Chemicals Limited
Indo Borax & Chemicals Limited Q2 FY27 results press release summary
NSE: INDOBORAX · BSE: 524342
Results press release of 11 Nov 2026, summarised by AI from the filing.
Company completed acquisition of 64.26% stake in Kronox Lab Sciences Ltd and appointed Mr. Suresh Kalra as MD & CEO at Kronox.
Key takeaways
- Kronox acquisition Company completed acquisition of 64.26% stake in Kronox Lab Sciences Ltd and appointed Mr. Suresh Kalra as MD & CEO at Kronox.
- Amalgamation Board approved amalgamation of Indoborax Infrastructure Private Ltd with Indo Borax Chemicals, subject to NCLT and other approvals.
- Margin pressure EBITDA margin under pressure from high raw material costs and Middle East geopolitical uncertainty.
Indo Borax & Chemicals Limited Q2 FY27 results
As filed: Revenue ₹58.9 cr (+2% year on year), EBITDA ₹1.5 cr (−87% year on year), PAT ₹4.8 cr (−69% year on year), EBITDA margin 2.5% (−1,000 bps).
The Q2 FY27 score, against the company's own trend, is for premium members.
Earlier results and the share price after them
- Q1 FY27: Revenue ₹70.4 cr (+30% year on year), EBITDA ₹19.8 cr (+65% year on year), PAT ₹16.3 cr (+63% year on year), EBITDA margin 28.1% (+592 bps). Score 78 of 100, Above trend. Revenue growth was above the company's own trend; EBITDA and profit growth were well above it. EBITDA margin rose 592 bps year on year. Share price after the results: +27.6% in 30 days (Nifty 500: −3.2%).
- Q4 FY26: Revenue ₹63.0 cr (+26% year on year), EBITDA ₹12.8 cr (+28% year on year), PAT ₹14.5 cr (+45% year on year), EBITDA margin 20.3% (+33 bps). Score 78 of 100, Above trend. Revenue growth was above the company's own trend; EBITDA and profit growth were well above it. EBITDA margin rose 33 bps year on year. Other income 26% of PBT. Revenue grew on the previous quarter, against its usual seasonal pattern. Revenue rose ₹13.0 cr on a year ago, more than the ₹5.0 cr it added the year before. Share price after the results: +32.4% in 29 days (Nifty 500: +2.5%).
- Q3 FY26: Revenue ₹41.0 cr (+8% year on year), EBITDA ₹8.6 cr (−22% year on year), PAT ₹9.3 cr (+3% year on year), EBITDA margin 21.0% (−791 bps). Score 37 of 100, Below trend. Revenue growth was above the company's own trend; EBITDA growth was below it; profit growth was in line with it. EBITDA margin fell 791 bps year on year. Other income 36% of PBT. Revenue fell 29% from last quarter. Share price after the results: −4.1% in 28 days (Nifty 500: −0.7%).
- Q2 FY26: Revenue ₹58.0 cr (+53% year on year), EBITDA ₹11.0 cr (+10% year on year), PAT ₹16.0 cr (+8% year on year), EBITDA margin 19.0% (−735 bps). Score 78 of 100, Above trend. Revenue growth was well above the company's own trend; EBITDA growth was above it; profit before exceptional items growth was in line with it. EBITDA margin fell 735 bps year on year. Revenue grew on the previous quarter, against its usual seasonal pattern. Share price after the results: +0.9% in 30 days (Nifty 500: −0.2%).
- Q1 FY26: Revenue ₹54.0 cr (+8% year on year), EBITDA ₹12.0 cr (−29% year on year), PAT ₹10.0 cr (−29% year on year), EBITDA margin 22.2% (−1,000 bps). Score 40 of 100, In line with trend. Revenue growth was above the company's own trend; EBITDA growth was below it; profit growth was well below it. EBITDA margin fell 1000 bps year on year. Share price after the results: −10.8% in 30 days (Nifty 500: +2.1%).
- Q4 FY25: Revenue ₹50.0 cr (+11% year on year), EBITDA ₹10.0 cr (−17% year on year), PAT ₹10.0 cr (−9% year on year), EBITDA margin 20.0% (−667 bps). Score 58 of 100, In line with trend. Revenue growth was well above the company's own trend; EBITDA growth was below it; profit growth was in line with it. EBITDA margin fell 667 bps year on year. Other income 31% of PBT. Revenue grew on the previous quarter, against its usual seasonal pattern. Share price after the results: +3.8% in 30 days (Nifty 500: +2.4%).
- Q3 FY25: Revenue ₹38.0 cr (−14% year on year), EBITDA ₹11.0 cr (+22% year on year), PAT ₹9.0 cr (+13% year on year), EBITDA margin 29.0% (+849 bps). Score 32 of 100, Below trend. Revenue growth was well below the company's own trend; EBITDA and profit growth were above it. EBITDA margin rose 849 bps year on year. Other income 29% of PBT. Tax rate 36%.
Past price moves after results do not indicate future moves. Not a recommendation.
Indo Borax & Chemicals Limited earnings call, investor presentation and press release summaries
Figures from the company's filings with NSE and BSE. Not investment advice.